Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Iressa: Phase I data

In a Phase I dose escalation trial of 64 patients with solid tumors

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE